Same coin, two sides. 4-Pro-MET is the prodrug; 4-HO-MET (metocin) is the active compound it converts into. Their effects are believed to be identical once conversion completes – both produce the same metabolite in the body. But they diverge sharply in onset speed, duration, chemical stability, and legal status. This comparison lays out every difference that matters when you're choosing between them.

4-Pro-MET is a prodrug of 4-HO-MET. Esterase enzymes cleave the propionyloxy ester group in the body, releasing 4-HO-MET as the active metabolite and propanoic acid as a benign byproduct. Because both routes end at the same molecule acting on 5-HT2A and other serotonin receptors, the subjective effects are expected to be pharmacologically identical once conversion finishes.

The real difference is timing. 4-HO-MET acts directly, producing effects within 10-20 minutes. 4-Pro-MET needs enzymatic conversion first, pushing onset back by an additional 10-40 minutes. And that delay isn't just a number – community reports consistently call 4-Pro-MET's come-up "smoother" and "more gradual" compared to 4-HO-MET's rapid onset.

One thing worth knowing for dosing: approximately 20% of 4-Pro-MET's molecular weight is the propionyloxy group, which gets removed before activation. So 20 mg of 4-Pro-MET delivers roughly 16 mg equivalent of active 4-HO-MET.

This is where the gap gets dramatic. 4-HO-MET's free hydroxyl group at position 4 is highly susceptible to atmospheric oxidation, producing dark degradation products and potency loss within days to weeks under ambient conditions. Psilocin – the structural analogue with N,N-dimethyl substitution – has the same problem. It's why mushrooms bruise blue: oxidation of the 4-hydroxyl.

4-Pro-MET's propionyloxy ester caps that vulnerable position, delivering months to years of stability under basic storage conditions. And that stability edge is one of the main practical reasons 4-Pro-MET has gained market traction since appearing in 2025 – it's simply far easier to store and ship without degradation.

In Germany, 4-HO-MET has been covered by the NpSG since July 18, 2019. 4-Pro-MET, as of April 2026, isn't listed in the BtMG and falls outside the NpSG's structural definitions. So the prodrug is legal while the active metabolite is regulated – a legal asymmetry that shapes 4-Pro-MET's entire market position. But this status could change at any time through legislative action.